Literature DB >> 28353596

Adult-onset hypophosphatemic osteomalacia associated with Sjogren syndrome: Clinical case report.

Guohua Shen1, Yuwei Zhang, Shuang Hu, Bin Liu, Anren Kuang.   

Abstract

RATIONALE: Hypophosphatemic osteomalacia (HO) is a metabolic bone disease, exhibiting different etiologies such as genetic mutation, tumor induction, dysimmunity, or renal disease. Sjogren's syndrome (SS) is a connective tissue disorder commonly involving exocrine glands; however kidney involvement is also encountered, leading to abnormal phosphorus metabolism, even HO. PATIENT CONCERNS: A 47-year-old female patient presented progressively worsening pain in the chest wall, back and bilateral lower extremities as well as muscle weakness was referred to our department. DIAGNOSES, INTERVENTIONS AND OUTCOMES: Due to the laboratory test results, radiographic findings and pathologic results, she was diagnosed with adult-onset HO associated with SS. She was then treated with alkalinization, steroids, neutral phosphate, calcium supplements together with activated vitamin D. So far, she recovered uneventfully with relieved pain and increased serum phosphorus level. LESSONS: HO may be secondary to renal tubular acidosis of SS patients, and it might be a diagnostic challenge when the kidney involvement in SS is latent and precede the typical sicca symptoms.

Entities:  

Mesh:

Year:  2017        PMID: 28353596      PMCID: PMC5380280          DOI: 10.1097/MD.0000000000006493

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Hypophosphatemia can cause an inadequate mineralization of the bone matrix, subsequently softening the bone and leading to osteomalacia.[ Hypophosphatemic osteomalacia (HO) is a metabolic bone disease, exhibiting different etiologies such as genetic mutation, tumor induction, altered immunity, or renal disease.[ Sjogren syndrome (SS) is a connective tissue disorder commonly involving exocrine glands; however, kidney involvement is also encountered.[ Renal tubular acidosis caused by tubulointerstitial nephritis might lead to abnormal phosphorus metabolism, even HO.[ Patients with HO usually present with clinical findings of bone pain, muscle weakness, and occasionally pathological fracture, with biochemical findings of serum hypophosphatemia, reduced active vitamin concentration, and increased alkaline phosphatase (ALP). For further etiological investigation, a wide variety of clinical, laboratory, and radiographic examinations were performed, which might delay the diagnosis. Here, we report one case showing multiple bone fractures due to HO in a patient with SS.

Case report

A 47-year-old female patient presented progressively worsening pain in the chest wall, back, and bilateral lower extremities as well as muscle weakness. She did not have a family history of bone disease or fractures. Physical examination was unremarkable excluding bone and muscular abnormalities. Bone scintigraphy using technetium-99m methylenediphosphate showed increased uptake in the shoulder, multiple ribs, thoracic and lumbar spines, bilateral sacroiliac joints, left ilium, and left foot (Fig. 1). Plain radiographs revealed osteoporosis change of thoracic and lumbar spine as well as compression change of several spines, consistent with findings of magnetic resonance imaging and computed tomography (CT) (Fig. 1). Decreased bone mass was presented in the lumbar spine (T-score: −3.4), femoral neck (T-score: −3.1), and hip (T-score: −3.5).
Figure 1

(A) whole body bone scintigraphy showed multiple foci of increased radiotracer uptake in the shoulder, multiple ribs, thoracic and lumbar spines, bilateral sacroiliac joints, left ilium, and left foot (arrow). (B) Plain radiographs revealed osteoporosis change of thoracic and lumbar spine as well as compression change of several spine. (C) MRI demonstrated osteoporosis and compression change of several thoracic spines (arrow). (D) CT showed degenerative changes and low bone density in the bilateral sacroiliac joints (arrow). CT = computed tomography, MRI = magnetic resonance imaging.

(A) whole body bone scintigraphy showed multiple foci of increased radiotracer uptake in the shoulder, multiple ribs, thoracic and lumbar spines, bilateral sacroiliac joints, left ilium, and left foot (arrow). (B) Plain radiographs revealed osteoporosis change of thoracic and lumbar spine as well as compression change of several spine. (C) MRI demonstrated osteoporosis and compression change of several thoracic spines (arrow). (D) CT showed degenerative changes and low bone density in the bilateral sacroiliac joints (arrow). CT = computed tomography, MRI = magnetic resonance imaging. Main laboratory data are shown in Table 1. She demonstrated hypophosphatemia, hypokalemia, hypouricemia, elevated level of ALP, C-telopeptides and chloride, and decreased carbon dioxide combining power. The urinalysis revealed a high pH value, increased level of potassium, and decreased level of specific gravity, chlorine, and phosphate. Persistent glycosuria and proteinuria were repeatedly found, despite normal HbA1c and plasma glucose level. Other laboratory test results including thyroid function test, serum parathyroid hormone, 25-hydroxyvitamin D, and protein electrophoresis were within normal range. In addition, all of serum tumor markers were negative. Due to limited technique, we cannot determine the level of serum fibroblast growth factor 23.
Table 1

Results of laboratory tests.

Results of laboratory tests. With the clinical diagnosis of HO, fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and technetium-99m octreotide (99mTc-OCT) scintigraphy were performed to confirm whether the occult causative tumor exist. However, the results of these 2 tests were negative except that mild uptake in the seventh rib was found on PET/CT, which identified no evidence of a neoplastic lesion potentially responsible for HO (Fig. 2). The immunological examination showed elevated level of serum IgG, IgM, and IgA, as well as positive antinuclear antibody, anti-SSA antibody, and rheumatic factor. Subsequently, Schirmer test was abnormal and lip biopsy supported the diagnosis of SS (Fig. 3). Eventually, this patient was diagnosed with HO secondary to SS, and she was then treated with alkalinization (citrate 4 g/day and potassium citrate 3 g/day for 2 weeks), steroids (prednisone 20 mg/day for 1 month, 10 mg/day for 4 months), neutral phosphate (1.0 g/day for 5 months), calcium supplements (600 mg/day for 5 months), and together with activated vitamin D (0.5 g/day for 5 months). So far, she recovered uneventfully with relieved pain and increased serum phosphorus level. This case report was approved by the ethics committee of West China Hospital of Sichuan University, Chengdu, China, and the written informed consent was obtained.
Figure 2

18F-FDG PET/CT only showed a mild uptake in the seventh rib which might be an insufficiency fracture (arrow) while the result of 99mTc-OCT was negative. 18F-FDG PET/CT = fluorodeoxyglucose positron emission tomography/computed tomography, 99mTc-OCT = technetium-99m octreotide.

Figure 3

Lip biopsy showed plasma cell infiltration around the salivary gland ducts, compatible with Sjögren syndrome.

18F-FDG PET/CT only showed a mild uptake in the seventh rib which might be an insufficiency fracture (arrow) while the result of 99mTc-OCT was negative. 18F-FDG PET/CT = fluorodeoxyglucose positron emission tomography/computed tomography, 99mTc-OCT = technetium-99m octreotide. Lip biopsy showed plasma cell infiltration around the salivary gland ducts, compatible with Sjögren syndrome.

Discussion

HO is a metabolic bone disorder characterized by abnormal phosphorus metabolism in bone mineralization. In these disorders, phosphatonins (phosphaturic hormones) inhibit renal tubular reabsorption of phosphate and reduce serum 1, 25-dihydroxyvitamin D level by mediating the several enzymes associated with vitamin D metabolism.[ In clinical practice, this disorder cannot be only induced by phosphaturic mesenchymal tumor,[ but also secondary to SS[ or hyperparathyroidism,[ even related to the adefovir therapy.[ Although the clinical symptoms of HO are unspecific or noncharacteristic, it is very important and valuable to reveal etiological cause of this disorder to provide appropriate therapy. As the most representative disorder, tumor-induced osteomalacia (TIO) is regarded as a paraneoplastic disorder of phosphaturic mesenchymal tumor. Most of these causative neoplasms are benign, presented with small size and slow growth rate and commonly located in peculiar or atypical sites so that their localization remains a challenge.[18F-FDG PET/CT, 99mTc-OCT scintigraphy, and 68Ga DOTATATE PET/CT played a considerable role in revealing TIO-associated tumors.[ For these patients with TIO, complete surgical resection of causative tumors is the definitive treatment. SS syndrome is an autoimmune disorder commonly involving exocrine glands including lacrimal and salivary glands, occasionally involving nonexocrine organs such as lung and kidney.[ Fanconi syndrome is a rare kidney manifestation in Sjögren syndrome, diagnosed by renal tubular acidosis along with glycosuria or proteinuria.[ Although the bone biopsy was not performed for our case, the diagnosis of HO was supported by the biochemical characteristics (serum hypophosphatemia, increased ALP) and imaging findings (osteoporosis, multiple fractures). The occurrence of HO in SS is due to the kidney involvement, including tubulointerstitial nephritis and tubular dysfunction.[ It is reported that most of SS patients demonstrated distal renal tubular acidosis, and abnormal phosphorus metabolism was usually related to the distal renal tubular acidosis while proximal renal tubular acidosis, just like Fanconi syndrome, is rarely encountered in SS patients.[ Another study demonstrated that the pathological phenotype of Fanconi syndrome might occur in not only distal but also proximal tubular dysfunction.[ In our case, the proteinuria and normoglycemic glycosuria indicated the presence Fanconi syndrome, meanwhile, our patient also showed some characteristics of distal tubular dysfunction such as alkalized urine. Hypophosphatemia was a result of long-term mixed distal and proximal renal tubular acidosis. In addition, HO is a very rare syndrome associated in 5% of cases with tertiary hyperparathyroidism due to long-term therapy with phosphorus and vitamin D.[ Adefovir, as an antiviral agent, is widely used in the management of patients with chronic hepatitis B. However, there is an increasing number of reports demonstrating that long-term use of adefovir can induce nephrotoxicity, even at a low dose.[ Quite evidently, adefovir therapy is not a reasonable explanation for our case. In conclusion, it is of importance to identify the potential cause of HO to choose an appropriate treatment. This disorder may be secondary to renal tubular acidosis of SS patients, and it might be a diagnostic challenge when the kidney involvement in SS is latent and precede the typical sicca symptoms.
  24 in total

1.  Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. 1965.

Authors:  K J Bloch; W W Buchanan; M J Wohl; J J Bunim
Journal:  Medicine (Baltimore)       Date:  1992-11       Impact factor: 1.889

Review 2.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Bone       Date:  2007-01-04       Impact factor: 4.398

Review 3.  Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review.

Authors:  Du Hwan Kim; Duk Hyun Sung; Yong Ki Min
Journal:  J Bone Miner Metab       Date:  2012-09-14       Impact factor: 2.626

4.  68Ga DOTATATE PET/CT is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia.

Authors:  Jingjing Zhang; Zhaohui Zhu; Dingrong Zhong; Yonghong Dang; Haiqun Xing; Yanrong Du; Hongli Jing; Zhen Qiao; Xiaoping Xing; Hongming Zhuang; Fang Li
Journal:  Clin Nucl Med       Date:  2015-08       Impact factor: 7.794

5.  Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.

Authors:  F Tartaglia; S Minisola; M Sgueglia; S Blasi; D Brunelli; E Degli Effetti; A Maturo; A Cola; F Custureri; F P Campana
Journal:  G Chir       Date:  2006 Jan-Feb

6.  Phosphatonins: physiological role and pathological changes.

Authors:  Loredana Cavalli; Celestina Mazzotta; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

7.  Oncogenic osteomalacia -- hypophosphataemic spectrum from "benignancy" to "malignancy".

Authors:  P Chiam; H C Tan; Y M Bee; M Chandran
Journal:  Bone       Date:  2012-12-06       Impact factor: 4.398

8.  Multiple bone fracture due to Fanconi's syndrome in primary Sjögren's syndrome complicated with organizing pneumonia.

Authors:  Hideki Nakamura; Junko Kita; Atsushi Kawakami; Satoshi Yamasaki; Hiroaki Ida; Noriho Sakamoto; Akira Furusu; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

9.  Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.

Authors:  Hongli Jing; Fang Li; Hongming Zhuang; Zhenghua Wang; Jian Tian; Xiaoping Xing; Jin Jin; Dingrong Zhong; Jingjing Zhang
Journal:  Eur J Radiol       Date:  2013-05-27       Impact factor: 3.528

10.  Renal involvement and followup of 130 patients with primary Sjögren's syndrome.

Authors:  Hon Ren; Wei-Ming Wang; Xiao-Nong Chen; Wen Zhang; Xiao-Xia Pan; Xiang-Ling Wang; Ying Lin; Su Zhang; Nan Chen
Journal:  J Rheumatol       Date:  2007-12-15       Impact factor: 4.666

View more
  2 in total

Review 1.  Tubulointerstitial nephritis-induced hypophosphatemic osteomalacia in Sjögren's syndrome: a case report and review of the literature.

Authors:  Yan Geng; Youlu Zhao; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2017-07-20       Impact factor: 2.980

2.  A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.

Authors:  Giuseppe Rosano; Ingolf Schiefke; Udo-Michael Göhring; Vincent Fabien; Stefano Bonassi; Jürgen Stein
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.